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                               INTRODUCTION
 Lower urinary tract symptoms (LUTS) due to benign prostatic enlargement 
(BPE) pose a significant impact on the quality of life of men around the 
world. Although modern medical therapies are the first choice in treating 
mild to moderate LUTS, surgical therapies remain the cornerstone in the 
treatment of BPE. Transurethral resection of the prostate (TURP) is the most 
common modality of surgical treatment for BPE, and has been the gold 
standard for the past few decades [1, 2]. Following TURP, a sizeable 
proportion of men have frequency and urgency that may continue for a few 
days  to several weeks. In the immediate post operative period, bladder 
discomfort due to an indwelling urinary catheter is distressing; more so in 
patients who have undergone a transurethral procedure, without going into 
retention. It is not unusual to find patients  complaining of an uncontrollable 
urge to void in the postoperative period because of catheter-related bladder 
irritation. Several modalities of  treatment have been tried with various 
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degrees of success for managing this troublesome side effect. The 
incidence of residual symptoms after TURP has been reported to be 
5-35% [3, 4]. In a 
study by Seaman and Blaivas, approximately 15 to 20% of patients who 
undergo transurethral resection of the prostate for benign prostatic 
hyperplasia have persistent or recurrent voiding symptoms requiring further 
therapy. The most common cause of persistent symptoms is detrusor 
overactivity (DO) [5, 6].
Similar symptoms of painful micturition have been reported following laser 
vapourisation of the prostate, and this apparently lasts longer and is more 
common than with TURP. It has been reported to be about 26% in a review 
by Hoffmann et al [7]. Irritating symptoms such as frequency  along with 
terminal dribbling and urgency are the most common complaints after 
catheter removal. We feel that the symptoms of frequency ,urgency and pain 
are worsened by the fact that there is a raw surface viz. the prostatic fossa 
that would cause irritation, and worsen such symptoms.
There has been a similar study by Iselin and Schmidlin [8], where the 
authors have used Oxybutynin for 5 days after TURP. They subsequently 
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evaluated symptoms using the Boyarsky score, and also performed 
urodynamic studies on the subjects. Based on this study we planned to 
evaluate the role of oxybutynin in alleviating post TURP lower urinary tract 
symptoms.
                                                          
                                             
AIM OF THE STUDY
The aim of the study was to evaluate the symptomatic effect of oral 5 mg 
Oxybutynin extended release, in the control of irritating voiding symptoms 
after trans urethral resection of the prostate(TURP).
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                                      REVIEW OF LITERATURE
Despite the impressive results of medical therapy for LUTS due to BPE, 
reported reductions (45–60%) in the IPSS on a representative a-blocker such 
as tamsulosin are inferior to TURP (up to 80% reduction in IPSS). In 
addition, reported improvements in maximum urinary flow rate (Qmax)
following treatment with tamsulosin (20–40%) are vastly inferior to those 
reported after TURP (80–90%). For these reasons, TURP is the preferred 
option for patients with severe LUTS or complications of BPE. Various 
studies quote coexisting bladder outlet obstruction combined with detrusor 
overactivity in 45% of the patients. Detrusor instability is common in men 
with evidence of outflow obstruction due to benign prostatic enlargement 
and typically reverses in about two thirds of patients after transurethral 
resection of the prostate (TURP). 
Early incontinence may occur in up to 30–40% of patients; however, late 
iatrogenic stress incontinence occurs in less than 0.5% of patients. Early 
incontinence is usually urge symptomatic, either because of irritative 
symptoms such as fossa healing and associated UTI or detrusor instability 
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caused by long-lasting BPH [9]. Few data reveal the relationship of the 
applied electric energy and the irritative symptoms postoperatively. 
Nevertheless, the amount of energy should be minimized. A smooth fossa 
with minimal residual necrotic tissue guarantees better healing and thus 
reduces the risk of chronic infection and irritative symptoms. 
Among patients discharged after TURP there is a considerable number of 
treatment-related symptoms in the first few weeks. In a study by Mogensen 
[10], 79.7% of patients who underwent TURP were incontinent due to 
urgency, to some degree.42% continued to have urgency for upto 4 weeks. 
Gormley et al [11] studied 12 males with a mean age of 80 years and 
performed urodynamic studies pre and post TURP. Postoperatively, 
although 8 became continent, they continued to have frequency and urgency 
after removal of the catheter. Preoperative urodynamic assessment of 
obstruction in the incontinent male with benign prostatic hypertrophy may 
be useful since the severity of incontinence responds well to TURP if there 
is marked obstruction.
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 Detrusor overactivity following TURP is frequently bothersome in the first 
few days after withdrawal of the bladder catheter. Various theories have 
been put forward for these symptoms. Surgical trauma and cauterization of 
the prostatic capsule possibly incites a local inflammatory reaction, which 
alters the activity of the neural afferents of the bladder base, leading to 
sensory urgency[8].
The tip of the transurethral catheter and its balloon may cause detrusor 
instability. In addition, perioperative bladder wall distension from the 
continuous irrigation may trigger short term tensile reactions in the detrusor 
smooth muscle. Changes in vascular perfusion of the bladder have also been 
implicated in triggering such responses. The latter was corroborated in a 
study by Mitterberger [12] et al, 50 subjects had persistent LUTS after 
TURP. These men were evaluated with quality of life scores, International 
Prostatic Symptom Score (IPSS), pressure flow studies and trans rectal 
Doppler ultrasound to assess the vascular resistance. When men with 
persistent storage symptoms (15 patients; group 1) were compared with 
those with no symptoms after TURP (35; group 2) there was a statistically 
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significantly higher RI of the bladder vessels in group 1, at 0.86 (0.068) than 
in group 2, at 0.68 (0.055) (P < 0.001). 
LUTS is present after TURP, but this undergoes significant improvement as 
time passes. In a study from Taunton, MacDonagh [13] and colleagues 
evaluated two groups of 314 patients, with the European quality of life 
index, alongwith the Nottingham Health Profile. There was a significant 
improvement in all LUTS 6 weeks after TURP; post-micturition dribbling 
and storage symptoms continued to improve for up to one year. 
In a study by Taylor et al, 71% patients had residual bothersome LUTS, the 
majority being urgency and urge incontinence [14]; several studies that 
suggest possibility of residual storage symptoms after TURP have been 
elucidated. Zhao et al [15] evaluated the changes of different urinary 
symptoms of patients with benign prostatic enlargement (BPE) after 
transurethral resection of the prostate (TURP) and its correlation with 
preoperative clinical parameters. Two hundred and eighty-one patients were 
followed-up immediately and 1 month after TURP, whose postoperative 
International Prostate Symptom Score (IPSS) and Quality of Life (QOL) 
score were compared with those preoperatively. Improvement of average 
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obstructive symptom score is greater than that of irritative symptom score. 
Among the seven symptoms, nocturia is the one with lowest improvement 
after TURP.
E. Mazaris et al divided prospectively and randomly 80 patients into 4 
groups of 20 each, who underwent TURP. Group A was the control group, 
in group B tamsulosin 0.4mg OD, in group C tolterodine 4mg OD and in 
group D a combination of tamsulosin and tolterodine in the aforementioned 
doses, were administered after catheter removal.They concluded that the 
administration of tolterodine for LUTS after TURP helps reduce the 
incidence and severity of urgency and urge incontinence and offers a better 
quality of life.
O’Sullivan [16] and colleagues studied  the effect of transurethral resection 
of prostate on quality of life (QOL) and urinary symptoms in patients with 
benign prostatic hyperplasia (BPH).They used four indices viz. the 
International Prostate Symptom Score , the Montgomery and Asberg 
Depression Rating Scale(MADRS), the McGill Pain Questionnaire(MPQ), 
and the QOL questionnaire Short Form-36. The MADRS score at 1 month 
(5.4) and 3 months (4.9) were lower than they were post-operatively (9.2). 
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The MPQ is a tool commonly used to evaluate acute and chronic pain. The 
sum of the rank values yields the pain-rating index and the greater the MPQ 
scores, the greater intensity of perceived pain. The MPQ scores were less at 
3 months than they were post-operatively.
There have been reports of painful micturition following LASER ablation of 
the prostate. In a study with 80 patients, Lane et al [17] compared visual 
analogue scores in groups who underwent prostatectomy with the Holmium 
Laser and in the other who had KTP laser prostatectomy. The visual 
analogue scores in the Holmium group were significantly higher than the 
KTP group, and this persisted till 3 weeks.
Irrigation of the bladder after transurethral resection of the prostate is often 
distressing because of pain arising from detrusor muscle spasm. The effect 
of post-operative oral diazepam was compared by Nott et al. Effects of 
diazepam, sacral epidural (caudal) block at the time of surgery, both 
treatments together and a control group, were assessed by three-point rank 
scoring. Either treatment significantly reduced the incidence of pain reported 
by patients, P < 0.001. No patient experienced pain after both treatments[18]
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Is it possible to predict which subgroup of patients, would continue to 
experience troublesome urgency and frequency after TURP? To answer that 
question, Kageyama [19] from Japan devised a novel study, in which they 
chose 14 subjects who had pre operative urodynamics alongwith single 
photon emission computed tomography (SPECT). They concluded that those 
patients who had decreased blood flow to the frontal cortex, as suggested by 
SPECT, were at increased risk of having persistent detrusor over activity in 
the post operative period. They also noticed that those with a bladder 
volume of less than 160 ml had increased risks of immediate postoperative 
symptoms.
There have been several other modalities in dealing with postoperative 
symptoms after TURP. Periprostatic nerve block at the time of TURP has 
been tried successfully by Gorur et al [20].  They included 40 male patients 
with benign prostatic hyperplasia who underwent TURP, and they were 
divided randomly into two groups. All patients were operated under general 
anesthesia. The study group of 20 patients received periprostatic bupivacaine 
(0.5% 20 ml) injection (group I), and the control group, also consisting of 20 
subjects, received only saline (NaCl 0.9% 20 ml) injection (group II). All 
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injections were performed bilaterally into the periprostatic areas 
immediately after the TURP procedure via the transperineal route. In the 
postoperative period, all patients (groups I and II) received tramadol using a 
patient-controlled analgesia device. Postoperative pain was assessed and 
recorded using the visual analog scale (VAS) at postoperative hours 1, 2, 3, 
4, 5, 6, 7, 8, 12, 16, 20, 24, and 48. Total tramadol consumptions and 
additional analgesic requirements were also recorded and compared between 
groups. They concluded that periprostatic bupivacaine administration was a 
useful and safe method for postoperative pain control and reduced analgesic 
consumption in patients undergoing TURP. 
Ricci and Minardi [21] evaluated patients who had undergone TURP and 
had sensory urgency. They used acupuncture reflexotherapy and compared it 
to placebo and oxybutynin, in patients who had urgency post TURP. 42 
patients were randomly selected into three groups: 14 patients received 
placebo, 15 patients received oxybutynin, and 13 patients were treated with 
electrostimulation by acupuncture reflexotherapy. At the first check-up at 1 
week, it was observed that the I-PSS and QoL scores were 12.6 +/- 4.3 and 
3.8 +/- 1.3 in the group who received placebo; the scores decreased to 11.1 
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+/- 3.2 and to 3.1 +/- 1.0, respectively, in the 15 patients treated with 
oxybutynin and decreased to 6.1 +/- 2.6 and 1.3 +/- 1.1, respectively, in the 
13 patients who underwent acupuncture reflexotherapy. The voiding diaries 
revealed that the average number of daytime voidings decreased by 8% in 
patients who received oxybutynin and decreased by 20% in 13 patients who 
underwent reflexotherapy; the average number of nocturnal micturitions 
decreased by approximately 20% and 60%, respectively, in patients who 
received oxybutynin and reflexotherapy.
   In the paediatric age group, catheter related bladder spasms are common. 
Park et al [22], in a group of children who had undergone ureteral 
reimplantation, showed that with use of a nonsteroidal anti-inflammatory 
agent viz. Ketorolac, there was a significant decrease in bladder spasms. 
Agarwal et al [23] used a single dose of tolterodine 2 mg in patients who had 
undergone transurethral surgery, and assessed the discomfort in the 
immediate post op period in the recovery room. There was an absolute risk 
reduction in symptoms of 19%. The number needed to treat was 5.
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Other anticholinergics like emepronium bromide (Cetiprin) have been used 
intravesically, and were found to be effective. The analgesic requirement in 
the group receiving Cetiprin was significantly lower [24].
Muscarinic receptors
Five different receptor types (M1–M5) have been identified, that vary in 
distribution throughout the body, depending on the particular organ system. 
In the bladder the predominant receptors are the M2 and M3 subtypes. 
Although the M2 subtype is the most abundant receptor in the bladder, it 
seems that the M3 receptor subtype is most directly responsible for the 
effects on the bladder, because it mediates detrusor contractility.
Oxybutynin and mechanism of action 
Oxybutynin chemically is 4-diethylaminobut-2-ynyl 2-cyclohexyl-2-
hydroxy-2-phenylacetate with a formula of C22H31NO3. It is a tertiary amine 
that exists commercially as a racemic mixture of R- and S-enantiomers (R-
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OXY, S-OXY). The mechanism of action of oxybutynin is 2-fold, consisting 
of (1) its antimuscarinic properties; and (2) its spasmolytic action on 
detrusor smooth muscle cells [25, 26]. Oxybutynin exhibits stereoselectivity: 
R-OXY has greater anticholinergic activity compared with S-OXY. The 
spasmolytic effects on smooth muscle seem to be equal for the R- and S-
isomers [27, 28]. In addition, oxybutynin resembles amines such as 
lidocaine and may have local anesthetic effects.
                                 Chemical structure of oxybutynin
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Studies from animal experiments have demonstrated that detrusor 
contractility occurs by M3 receptor-mediated smooth muscle contraction 
through hydrolysis of phosphatidylinositol and release of intracellular 
calcium. Furthermore, there is also evidence that M2 receptor-mediated 
contractions occur through inhibition of cyclic adenosine monophosphate- 
mediated relaxation of detrusor smooth muscle. As a result, by binding to the 
M2 and M3 muscarinic receptors of urothelial and detrusor smooth muscle 
cells, oxybutynin exerts its therapeutic effect by interrupting signal 
transduction pathways that cause detrusor contraction.
Oxybutynin binds to M3 muscarinic receptors on the detrusor muscle of the 
bladder, preventing acetylcholinergic activation and relaxation of the 
muscle.
Extended-release oxybutynin uses an osmotic system (OROS) to deliver a 
controlled amount of oxybutynin chloride into the gastrointestinal tract over 
a 24-hour period when taken once daily [29]. It resembles a conventional 
tablet but has a two-part core consisting of a drug layer and below it, a 
"push" layer containing osmotically active components, the whole 
surrounded by a semipermeable membrane with a laser-drilled opening in 
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the drug layer. Water in the gastrointestinal tract enters the tablet and mixes 
with the drug to form a suspension. The "push" layer expands and pushes the 
suspended drug out of the orifice and into the gastrointestinal tract for 
eventual absorption [30] Pharmacokinetic studies have indicated a slow rise 
in mean plasma concentration of the isomer R-oxybutynin for 4 to 6 hours 
after a single dose of OROS oxybutynin, followed by maintenance of steady 
concentrations for up to 24 hours, minimizing the fluctuations between peak 
and trough associated with TID dosing of 5-mg immediate-release 
oxybutynin tablets.
Oxybutynin metabolism
Oxybutynin is extensively metabolized by first-pass hepatic metabolism 
after administration of an oral immediate-release dose. The cytochrome 
P-450 (CYP) isoenzymes are the most abundant drug-metabolizing 
cytochromes in the liver and small intestine, mediating phase I drug 
metabolism through oxidation, reduction, and hydrolysis. CYP-3A4 is a 
specific cytochrome that converts oxybutynin to its active metabolite, N-
desethyloxybutynin (N-DEO). As a result, bioavailability after oral dosing 
of 
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oxybutynin is only 6%, with levels of N-DEO reaching peak plasma 
concentrations that are 4 to 10 times greater than the native compound. 
Because of the high affinity of N-DEO for muscarinic receptors, particularly 
in the parotid gland, it is generally accepted that many of the anticholinergic 
adverse effects observed after oral dosing of oxybutynin are secondary to 
high circulating levels of its active metabolite, N-DEO.Oxybutynin was 
rapidly absorbed, maximum plasma concentrations (8 ng.ml-1) being 
reached in less than 1 h. The absolute systemic availability averages 6% and 
the tablet and solution forms display similar relative systemic availability. 
Plasma concentrations of oxybutynin fall biexponentially, the elimination 
half-life being about 2 h. Oxybutynin chloride has a long history of safety 
and efficacy dating back to the mid-1960s, when it was originally approved 
for the management of detrusor hyper-reflexia secondary to neurogenic 
bladder dysfunction. Originally developed by Majewski, oxybutynin was 
patented in1965. Oxybutynin has both musculotropic relaxant activity and 
local anesthetic activity, and has been one of the most extensively studied 
agents in this pharmacologic group Early studies of the drug using 
cystometrography in patients who had neurogenic bladders and upper motor 
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neuron disorders proved the drug effective in controlling urinary urgency, 
frequency, and incontinence. The US Food and Drug Administration (FDA) 
eventually approved oxybutynin in 1975 for the treatment of uninhibited and 
reflex neurogenic bladders and for the treatment of enuresis in patients older 
than 5 years. In the early 1980s, oxybutynin was found efficacious not only 
for those who had neuropathic disturbances but also for patients who had
detrusor overactivity without known neuropathic disturbance. In 1980, 
Moisey and colleagues reported the results of a randomized double-blind 
study in 30 patients who had detrusor instability. Their findings suggested 
that the drug provided subjective improvement of symptoms in most of the 
patients treated, with urodynamic improvement in half of the patients 
completing the study. This study and others allowed oxybutynin to gain 
FDA approval for its use in detrusor instability in 1992. Over the last few 
decades, oxybutynin has demonstrated efficacy and safety in several clinical 
trials
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 Safety and tolerability  
The use of oxybutynin since the early 1960s has afforded clinicians the 
ability to thoroughly evaluate its safety and efficacy. One of the early 
clinical trials of oxybutynin evaluated it as therapy for irritable bowel 
syndrome and established its most common adverse events, namely, 
constipation, dry mouth, and visual disturbances. In a trial where efficacy of 
extended release agents for overactive bladder were studied, 
A secondary goal of the trial was to evaluate tolerability of extended-release 
oxybutynin by patient-reported adverse events. In this study, most adverse 
events were those that would normally be expected in patients treated with 
anticholinergic agents. Dry mouth was reported in 28.1% of patients, with 
other side effects being headache (8.1%), constipation (7.0%), and dyspepsia 
(5.9%). Extended-release oxybutynin was well tolerated in the OPERA 
(overactive bladder-performance of extended release agents) study, with 
total dry mouth being the most common adverse event (29.7%), which was 
statistically different (P = 0.05) from those taking long-acting tolterodine 
(22.3%). Both groups showed a similar rate of discontinuation of therapy 
due to adverse events (w5% for each group). Other adverse events noted in 
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the study were mild or moderate dry mouth, diarrhea, constipation, 
headache, and urinary tract infection. In a recent trial, extended-release 
oxybutynin was evaluated over up to a 12-month period to study the long-
term safety profile. This multicenter trial followed a total of 904 women and 
163 men using quality-of-life assessments to measure the impact of 
incontinence and evaluate treatment outcome with extended-release 
oxybutynin. In this study, most discontinuations were in the first 3 months 
(25.5%) and were related to adverse events, most commonly dry mouth 
 (8.4%). Of those continuing after 3 months, 62% remained on extended-
release oxybutynin for 1 year. Patients had significant improvements in 
quality of- life measures in this multicenter trial [31].
Because oxybutynin and its extended-release form are tertiary amines, they 
can theoretically cross the blood-brain barrier and produce central nervous 
system adverse events. Central nervous system adverse events of 
oxybutynin, including somnolence, dizziness, and insomnia, were limited in 
the OPERA study and were similar to tolterodine. The incidence of central 
nervous system adverse events was reported at rates between 1.2% and 4.3% 
for extended-release oxybutynin and between 1.1% and 5.2% for extended-
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release tolterodine over the entire study period. These adverse events led to 
early discontinuation by only 1.5% of the participants taking extended-
release oxybutynin and 0.5% of participants taking extended-release 
tolterodine. This difference was not statistically significant [32].
Why oxybutynin?
Bladder discomfort related to an indwelling catheter can exacerbate 
postoperative pain. It mimics overactive bladder syndrome that is resistant to 
conventional opioid therapy. Muscarinic receptor antagonists are effective 
for treatment of the overactive bladder.
Although a single study in the late seventies by Wein [33] and co workers 
showed no benefit with 10 or 20 mg oxybutynin in relieving bladder spasms, 
there have been many subsequent reports to the contrary.
Tauzin-Fin P [34] et al used sublingual oxybutynin in patients who 
underwent radical prostatectomy, and were on a catheter. Oxybutynin 5mg 
was given 8 hourly for 24 hours to one group, along with placebo to the 
control. A 16F Foley catheter was placed during the vesico-urethral 
anastomosis and the balloon inflated with 10 ml of saline. Pain was assessed 
in the recovery room starting 10 min after extubation using a 100-point 
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visual analogue scale (VAS). The patients were asked to specify whether 
pain was related to the surgical incision or bladder pain. Standardized 
postoperative analgesia included acetaminophen and tramadol administered 
via a patient-controlled analgesia system. They concluded that sublingual 
oxybutynin was an effective treatment for postoperative pain after radical 
retropubic prostatectomy and produces a significant reduction in tramadol 
requirements.
Kirkali and Whitaker [35] administered oxybutynin to 216 patients with 
LUTS or with a catheter in situ. Good results were obtained in 66% of 
patients who had no previous treatment and in 46% of patients who had 
taken various drugs before. It was just as effective in all age groups. Twenty-
three per cent of patients experienced side effects and 10% were unable to 
tolerate the drug. They concluded that oxybutynin was an effective drug in 
the treatment of unstable bladder catheter-induced spasms.
Oxybutynin chloride and placebo were randomized in a double-blind trial to 
determine the effectiveness of the test agent in controlling post-transurethral 
pain and spasm [36]. Oxybutynin chloride was found effective in controlling 
pain and spasm; no significant side effects were noted.
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In animal studies, oxybutynin chloride was found to exert a moderate 
anticholinergic effect on rabbit detrusor in vitro, which is reversible and 
competitive in nature and midway in potency between atropine and 
papaverine [37]. In addition, oxybutynin strongly antagonizes BaCl2-
induced spasms of detrusor with a potency equivalent to that of papaverine 
and 10 times that of atropine. This musculotropic spasmolytic effect is 
slightly greater in rabbit than human or monkey tissue. This direct relaxant 
effect, unlike that of papaverine, is not mediated by the inhibition of tissue 
phosphodiesterase, but probably reflects oxybutynin's local anesthetic 
properties and associated effects on Ca++ fluxes and binding.
Oxybutynin chloride, a tertiary amine possessing anticholinergic and 
papaverine-like, direct muscular antispasmodic effects, has been used in 
controlled clinical studies in patients with neurovesical dysfunction, upper 
motor neuron bladders, enuresis, and primary muscle spasm. The 
cystometrically documented, synergistic, anticholinergic, and muscle 
relaxant activity of oxybutynin observed in these studies indicates that the 
drug can be highly effective in the management of reflex neurovesical 
dysfunction, enuresis, and bladder spasm. [38]. Oxybutynin is widely used 
in patients who have neurogenic bladder dysfunction. Bennett and 
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colleagues [39] evaluated the efficacy and safety of high-dose oxybutynin 
chloride in patients who had multiple sclerosis, spinal cord injury, and 
Parkinson’s disease. This trial was a prospective, 12-week dose-titration trial 
of extended-release oxybutynin. Doses were increased by 5 mg at
weekly intervals to a maximum dose of 30 mg daily. Patient perception of 
efficacy versus side effects directed dose escalation. Of 39 patients enrolled 
in the study, 22 had multiple sclerosis, 10 had spinal cord injury, and 7 had 
Parkinon’s disease. Within 1 week of treatment, over half of the patients 
reported a decrease in the number of voids per day, and at the end of the 
study, there was a statistically significant decrease in 24-hour voids, 
episodes of nocturia, and incontinence episodes. Most (74.4%) patients in 
this study requested higher doses (15 mg or greater) of extended-release 
oxybutynin, and therefore, these investigators concluded that in this 
population, doses of up to 30 mg may be more effective. 
Oxybutynin has also been used in the intravesical form; in children with 
neurogenic bladders Adjunctive intravesical oxybutynin therapy increased 
mean maximum bladder capacity and decreased bladder pressure in children 
with neurogenic bladder [40].
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However, identified studies offered a low level of evidence, with most being 
poorly reported retrospective case series with potential biases. Although the 
incidence of side effects was lower with the intravesical route, side effects 
are still possible. To improve patient compliance and tolerability, alternative 
delivery systems for oxybutynin have subsequently been developed and 
include a once-daily formulation and a transdermal system. Oxybutynin 
chloride has been reported to be equally effective when given intravesically, 
transdermally, or in intrarectal form. Saito and colleagues [41] reported their 
3-year experience of using a modified intravesical form (oxybutynin 
chloride with hydroxypropylcellulose) in patients who had neurogenic 
overactive bladder and were not satisfied with the oral form of the drug or 
other therapies. Cystometrography was used to evaluate patients before 
treatment, at 1 week, and at 3 years after the initial intravesical treatment. 
This study was limited to six patients whose mean bladder capacity before 
treatment was 129.7 mL. Cystometrography studies revealed that bladder 
capacity increased to 283.5 mL and 286.8 mL at 1 week and 3 years post-
treatment, respectively.
Transdermal forms of oxybutynin chloride are available and deliver the drug 
over a 3- to 4-day period after application to intact skin. Dmochowski and 
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colleagues [42] evaluated transdermal oxybutynin and randomized 520 adult 
patients to receive 1.3, 2.6, or 3.9 mg daily. Voiding diaries and 
incontinence-specific quality of life were part of the evaluation. In this 
study, the highest dose (3.9 mg) was associated with a significant reduction 
in the number of weekly incontinence episodes and daily urinary frequency, 
significantly increased mean voided volume, and improved quality of life. 
Using 2.6 mg increased mean voided volume. In a second large, randomized, 
double-blind trial, efficacy of 3.9-mg oxybutynin administered 
transdermally was compared with placebo. Oxybutynin significantly 
decreased the number of incontinent episodes per week compared with 
placebo (P ¼ 0.0165). In addition, the transdermal form reduced micturition 
frequency and increased voided volumes. Side effects of the transdermal 
form were mainly related to the site of application. Dry mouth and other 
adverse events associated with the oral form and other anticholinergics were 
less common in transdermal oxybutynin [43]. Few studies have evaluated 
intrarectal administration of oxybutynin. In another study, patients not 
tolerating oral oxybutynin were offered an intrarectal form of oxybutynin. 
Fifteen patients who consented to the study were given 5 mg of intrarectal 
oxybutynin chloride twice daily. 
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After switching to the intrarectal route of administration, none of the patients 
chose to discontinue the treatment. All patients reported an improvement in 
their symptoms of overactivity, with 25% of patients claiming their 
symptoms had completely disappeared. Only 13.3% of patients reported 
mild-intensity dry mouth [44]. Although oxybutynin chloride has been 
studied in many routes of administration, the oral route is the most 
thoroughly evaluated and commonly used form. The enteral route of 
administration should be attempted first in most patients. Patients not 
tolerating oral oxybutynin can be tried on another form.
Despite the amply demonstrated efficacy and safety of antimuscarinic 
medications in appropriately selected female and male populations with 
symptoms of OAB some experts have expressed concern over the potential 
effects of these agents on peak flow rate and PVR volume in male patients 
with LUTS associated with BPE.
However, the fear of retention is ill founded. Chapple and Roehrborn [45] 
emphasised that male OAB symptoms are storage LUTS that may
coexist with bladder prostatic hyperplasia (BPH),bladder prostatic
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enlargement (BPE), or BOO without being caused by the prostatic condition. 
The safety of the use of antimuscarinic drugs can be explained by the fact 
that these drugs act mainly by decreasing the urge and increasing bladder 
capacity during the filling phase, when there is no activity in the 
parasympathetic nerves releasing acetylcholine.
Hence, it can be hypothesised that the drugs block the afferent nerves 
initiating the micturition reflex, triggered by a tonic release of acetylcholine
from nerves or, perhaps, from the urothelium.
Moreover, being competitive antagonists, the action of these drugs can be 
reduced during the voiding phase, when there is a massive release of 
acetylcholine. Hence, this may be the reason why the currently used dosages 
of antimuscarinic drugs do not lead to urinary retention.
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                       MATERIALS AND METHODS
The study was carried out in the department of urology of the 
Christian Medical College.
Inclusion criteria
All patients undergoing TURP were included for the study
Exclusion criteria
1) Carcinoma prostate
2) Underlying neurological disease
3) Vesical calculus
4) Bladder diverticulum
Study type
Randomized, double blind, placebo controlled trial.
Method of randomization 
Block randomization method was used for this study. They 
were stratified into blocks of 10 subjects each.
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A pilot study was initially performed and 20 subjects who had 
undergone TURP were assessed for presence of irritative 
symptoms. 13 patients had severe symptoms after TURP. Of 
these, 7 were given oxybutynin and 6 were not. The frequency 
and urgency in all 7 were less than in those who did not receive 
oxybutynin. With this background, and the previous study viz. 
Iselin/Schmidlin’s, using  oxybutynin, it was assumed that there 
would be a difference of 38% in the treatment and placebo arm 
(84% in treatment arm and 46% in placebo, according to 
Iselin’s study).   
Sample size calculation
Power of study 90%
Alpha error        5%
Detection of 84% in treatment response, and 46% in placebo, 
with a power of 90% and  5% level of significance(2 sided) the 
sample size for each group was 40 per group.
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Patients who were eligible, were consented in their own 
language prior to  inclusion in the study.
All patients had a preoperative self assessment  IPSS 
score(International Prostate Symptom Score).
TURP was carried out using monopolar cutting loop electrode, 
with Iglesias continuous flow resectoscope. There was a varied 
cadre of surgeons who performed the TURP’s.
The patients were then randomized to receive 5 identical 
tablets of oxybutynin 5mg XL or placebo. The packaging of the 
drug and the placebo was done by the pharmacy department of 
the institution, according to the random code generated. The 
packets were opaque, white and were numbered serially. The 
drug was dispensed by a nurse, who had no information about 
the contents of the packet, or the patient receiving it. Neither 
the investigator nor the patient knew which medication was 
being given to him.
Patients were instructed to take 1 tablet at bedtime for the 
following 5 consecutive days, beginning the day after surgery.
                                                       32
Catheters were removed on the 3rd post operative day, in the 
morning. IPSS score, visual analogue score, frequency of 
micturition, 
nocturia,bladder diaries were monitored for the 1st, 3rd and 5th 
post op days; post void residue was recorded on the 3th post 
operative  day. Side effects, if any were recorded.
Statistical analysis
Mean and standard deviation of IPSS scores, visual analogue 
scores, frequency , nocturia and post void residue were 
calculated. Differences in day 3 and day 5 from baseline were 
computed to test for statistical significance. SPSS package 16.0 
was used for computing the statistical analysis.
                                         The IPSS score
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 The visual analogue score
The Wong Baker face scale was used for assessing pain and discomfort after
 the TURP. This is used as a measurement that tries to measure a 
characteristic or attitude that is believed to range across a continuum
of values and cannot easily be directly measured.
All patients were administered this pain scale and these were then computed 
along with the IPSS, bladder diary and post void residue.
.
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RESULTS
There were 70 subjects who were enrolled. However 20  patients of the 70 
failed to complete their bladder diaries, and  were excluded from the 
analysis. Hence the analysis was undertaken for 50 subjects only.
The mean age in both the groups were evenly matched, as were all other 
parameters viz. IPSS, visual analogue score, frequency of micturition, 
nocturia , fluid intake, post void residues, and gland size.
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                                          Descriptive statistics
Variables
Oxybutynin Placebo
         Mean±SD Mean±SD
Age
International Prostate 
Symptom Score
Baseline
Day1
Day3
Day5
Visual Analog Scale
Day1
Day3
Day5
Frequency of Urination
Day1
Day3
Day5
Nocturia
Day1
Day3
Day5
Fluid Intake(ml)
PVR(ml)
Gland size in gm
66.46±8.25
27.42±3.74
26.19±3.89
25.04±3.84
23.88±3.83
4.27±0.67
2.62±0.75
2.00±0.98
9.92±1.49
7.81±1.92
7.35±1.96
1.42±0.58
1.23±0.59
0.92±0.69
2913.46±523.12
30.46±11.78
31.73±9.59
65.21±6.55
28.12±3.35
26.37±3.37
25.21±3.02
24.67±3.21
4.17±0.76
2.83±0.82
2.04±1.08
9.79±1.91
8.29±2.07
7.78±1.88
1.62±0.58
1.21±0.41
1.08±0.72
2858.33±507.39
33.71±20.21
29.17±11.76
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                           IPSS trends over 1  st  , 3  rd   and 5 th   day 
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Analysing the IPSS trends over the 1st, 3rd and 5th day,  showed a decreased 
score in both the drug and the placebo arms. However, the difference in 
mean IPSS scores were most at the 3rd day, and this begun to plateau by the 
5th day (Fig 1)
Oxybutynin    
Placedbo          -----
     Fig. 1
The histogram below shows that the frequency of change in IPSS scores 
followed a normal distribution curve, with an overall mean change of 3.5 
points, with a S.D. of 2.188
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         Fig. 2: IPSS change from day 1 to day 5
VAS:
Fig 3: Change in VAS from day 1 to day 5
The above histogram (Fig 3) shows a Gaussian distribution of the subjects 
who had change in the VAS .The overall mean change was 2.2 points on a 
scale of 6, and the S.D was 1.107.
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                                                              Fig. 4
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Oybutynin   ___
Placebo        -----
The mean VAS (Fig 4) in the oxybutynin group was lower than the control 
group, but this was also more marked on the 3rd day( 2.5 as compared to 3 in 
the placebo group). By the 5th day , the mean VAS scores of both groups had 
reduced.
Frequency of micturition:
Fig 5: Change of frequency of micturition  from day 1 
to day 5
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    Fig. 6
                                                          
Analysing the change in frequency of micturition, there was an appreciable 
change in the frequency , in the oxybutynin group( Fig 6) . This became 
more pronounced as the 5th day approached, and although there was a 
                                                         43
decrease in the control group also, the difference in overall change was 18%. 
This was probably significant at 7% error.
Nocturia:
The above histogram (Fig 7)shows the mean change in nocturia episodes 
from day 1 to day 5. The overall  mean change was 0.30 and the S.D was 
0.505.
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Oxybutynin   ___
Placebo        -----
Fig 7:  Change in Nocturia episodes from day 1 to day 5
                                                              
Nocturia was again less in episodes, especially on the 5th day(Fig 8) , where 
the graph shows a difference of nocturia episodes from 1.1 nocturia episodes 
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   Fig 8
in the placebo group as compared to 0.9 in the drug group. Though the 
difference is small and not statistically significant, there is indeed a 
difference in the values which become pronounced at the 5th day.
                      
                     Consolidated efficacy analysis
                               Efficacy analysis for  IPSS
                                          
 
                                                          46 
  
Variable OxybutyninMean±SD
Placebo
Mean±SD
Mean 
Difference p value
IPSS Change from 
Baseline to Day1
IPSS Change from 
Baseline to Day3
IPSS Change from 
Baseline to Day5
1.75±1.32
2.91±1.76
3.53±2.40
1.23±1.50
2.38±2.19
3.45±1.98
0.519
0.532
0.801
0.203
0.352
0.899
Efficacy analysis for  Visual analogue score
 
                       
                     Efficacy analysis for  frequency of micturition
Variable OxybutyninMean±SD
Placebo
Mean±SD
Mean 
Difference
p 
value
VAS Change from 
Day1 to Day3
VAS Change from 
Day1 to Day5
1.33±0.64
2.27±1.00
1.65±0.74
2.10±1.23
-0.320
0.144
0.110
0.650
Variable OxybutyninMean±SD
Placebo
Mean±SD
Mean 
Difference p value
Frequency of Urination 
Change from Day1 to 
Day3
Frequency of Urination 
Change from Day1 to 
Day5
2.11±1.70
2.58±1.90
1.50±1.72
2.13±1.66
0.615
0.446
0.210
0.389
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                                     Efficacy analysis for Nocturia
Other outcomes:
There was no difference in the mean fluid intake between the two groups. 
Post void residue in both the groups were comparable with mean of 30.46 ml 
in the study group and 33.71 ml in the placebo group. It is noteworthy that 
Variable OxybutyninMean±SD
Placebo
Mean±SD
Mean 
Difference
p 
value
Nocturia Change 
from Day1 to Day3
Nocturia Change 
from Day1 to Day5
0.416±0.50
0.54±0.72
0.19±0.49
0.50±0.65
0.2243
0.042
0.118
0.831
the PVR was actually higher in the placebo group, thus ending all 
speculation about the theoretical possibility of retention with oxybutynin.
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Adverse effects:
6 of the 24 in the oxybutynin group (25%) and 5 of the 26(20%) in the 
control group complained of dry mouth. However none of the patients 
discontinued the drug, probably because this ended by the 5th day.
None of the patients in the control or study group developed retention.
                                     
                                                
                                                   DISCUSSION
Many patients are bothered by lower urinary tract symptoms immediately or 
at some time after prostatectomy for benign disease. Pain only arises during 
urination for the first time after the removal of urinary catheter; this has been 
described by  some as a "sharp pin-point" pain. Many studies have addressed 
this issue, and the incidence of recurrent or persistent symptoms has been 
reported to be 5-35%. Post-prostatectomy voiding dysfunction can be 
divided into subjective problems, or symptoms and objective problems as 
determined urodynamically. When assessing symptoms, investigators have 
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noted that urgency and frequency occur in 45 to 75% of patients before and 
20 to 35% after prostatectomy. It has been found that symptoms remaining 
with the greatest scores even at 3 months postoperatively are frequency, 
urgency and nocturia.
This study was aiming to answer whether oxybutynin could reduce the 
storage symptoms seen in the immediate post TURP period. One of the draw 
backs of this study was that urodynamic evaluation was not carried out. 
However, it is our department policy not to subject everyone undergoing 
TURP for pressure flow studies (PFS). PFS is reserved for specific 
indications viz. young males with BOO, established neurological disease 
and predominant storage symptoms in the IPSS. The first two categories of 
patients were excluded from this study, and none of the patients included 
had predominant storage LUTS.
Our sample size calculation was based on the Swedish  study where in the 
difference showed in frequency was 38%. However, a closer statistical 
analysis of the same revealed that the previous study did not measure 
effective change of frequencies between the 2 groups.
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Our results were different from the Swedish study, the reasons for which 
may be multifactorial. 
Efficacy analysis did show at least an 18% benefit of the drug over placebo. 
The change in IPSS scores (p=0.352 at day 3), visual analogue score 
(p=0.110 at day 3), frequency of micturition (p=0.389 at day 5) and nocturia 
(p=0.118 at day 3) all showed a modest benefit. However this was not 
statistically significant. Of all the variables, except frequency of micturition, 
the maximum change between the two groups was on the 3rd day. 
Whether this is of sufficient benefit to the patient, needs to be evaluated 
further.
The present study probably is underpowered and hence a statistically 
significant benefit is not evident in the results.
A larger sample size may give more information in this regard.
What is indeed novel is the simplicity of the design, and the fact that a 
simple, widely used drug, may alleviate bothersome symptoms.
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                                 CONCLUSION
Our hypothesis is that the frequency and urgency following TURP is 
partly due to the created raw surface of the resected prostatic fossa, 
that triggers overactivity, and that this can be reduced with 
anticholinergics. This is different and apart from the overactivity that 
is present due to BOO.
Detrusor overactivity associated with aging and benign prostatic 
obstruction often causes the troublesome symptoms of urgency and 
urgency incontinence. Persistent detrusor overactivity after 
transurethral resection of the prostate is the cause of more than a third 
of poor symptomatic outcomes following surgery.
Most of the evidence currently suggests that neurons of the urothelium 
at the bladder neck play a significant role in the genesis of detrusor 
overactivity. Anticholinergics have a definite and proven role to play, 
especially in the immediate post operative period. A short course of a 
proven anticholinergic like extended release Oxybutynin, alleviates 
the rather bothersome symptoms of urgency, increased frequency, and 
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also reduces pain in the immediate post operative period. The 
apprehension about possibility of retention due to anticholinergic is ill 
founded and none of the patients on oxybutynin had urinary retention.
An  improvement in frequency and nocturia was observed on the 5th 
day and nocturia, as also a decrease of pain during micturition, as 
evidenced by improvement in the visual analogue score.
From this study there is inadequate evidence to suggest routine use of 
anticholinergics after TURP, to reduce symptoms of frequency and 
urgency in the immediate postoperative period.                                
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